Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-05 21:13 • The Motley Fool Positive Axe Cap view: Selective

The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.

Axe note: Nasdaq's rally on tech optimism contrasts with rising US Treasury yields, creating a complex backdrop for rand investors.

2026-10-05 21:00 • The Motley Fool Positive Axe Cap view: Selective

Vale surged 2.83% to $14.15 on Oct. 5, 2026, following Brazil's presidential election where conservative candidate Flávio Bolsonaro took a surprise lead in the first round. Investors believe his potential victory could create a favorable fiscal and regulatory environment for miners like Vale. The stock jumped on elevated trading volume of 98.9M shares, with investors also awaiting Vale's late-October earnings report.

Axe note: Vale rallies on Brazil’s election surprise, lifting South African mining peers.

2026-10-05 20:20 • The Motley Fool Mixed Axe Cap view: Selective

Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.

Axe note: Eli Lilly’s rapid rise on GLP-1 drugs faces growing risks amid stiff competition and lofty valuations.